I-Corps: Polysialic Acid Based Nanocarriers as Platforms for Targeted Drug Delivery

拟议的项目旨在教育首席调查员和企业领导人如何将他们的药物输送技术转化为市场，以提高社会效益。由此带来的现有药物输送的改善将使那些患有潜在致衰性疾病的人受益，这些疾病包括类风湿性关节炎、囊性纤维化、外周动脉疾病和癌症。预计拟议的药物输送技术将在制药和生物技术工业中得到应用。拟议的药物输送技术旨在通过使用基于聚唾液酸(PSA)的纳米载体来改善药物的特定部位输送。由于非特异性靶向和免疫原性反应的诱导，传统疗法和新开发的疗法往往与严重后果相关。近年来，研究范式已经转向将有毒药物与分子载体相结合，目的是促进专门给药到患病区域，从而提高疗效并减少副作用。据设想，拟议的以纳米颗粒和胶束形式的基于PSA的纳米载体系统将在制药和生物技术行业中使用，以改善传统的小分子疗法以及最近开发的治疗性生物制剂的输送。

The proposed project is intended to educate the principal investigator and the entrepreneurial lead on how to translate their drug delivery technology to the marketplace so as to enhance societal benefits. The resultant improvements to existing drug delivery will benefit those who suffer from potentially debilitating diseases, including rheumatoid arthritis, cystic fibrosis, peripheral artery disease, and cancer. It is envisioned that the proposed drug delivery technology will find use in the pharmaceutical and biotechnology industries.The proposed drug delivery technology is aimed at improving the site-specific delivery of drugs by using polysialic acid (PSA)-based nanocarriers. Conventional and newly developed therapeutics are often associated with severe consequences due to non-specific targeting and induction of immunogenic responses. In recent years, paradigms have shifted towards combining toxic drugs with molecular vehicles intended to promote delivery exclusively to the diseased region, thereby increasing efficacy and reducing side effects. It is envisioned that the proposed PSA-based nanocarrier systems, in the form of nanoparticles and micelles, will find use in the pharmaceutical and biotechnology industries to improve the delivery of both conventional, small molecules therapeutics, as well as recently developed therapeutic biologics.